| 摘要: |
| ［摘要］ 目的 观察厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的疗效及预后。方法 选取2013-05～2015-07该院收治的非小细胞肺癌脑转移患者90例，随机分为对照组和观察组，各45例。对照组采用全脑放疗治疗，共2周，总剂量为30 Gy/10 Fx。观察组在放疗的基础上联合厄洛替尼150 mg/d，共2周。对比两组临床疗效、预后情况及不良反应发生率。结果 观察组完全缓解3例，部分缓解25例，稳定13例，进展4例。对照组完全缓解1例，部分缓解16例，稳定11例，进展17例。观察组临床疗效优于对照组（P<0.01）。观察组平均生存时间及生存率均明显高于对照组，差异有统计学意义(P<0.05)。两组患者不良反应发生率比较，差异无统计学意义（P>0.05）。结论 厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移临床效果显著，可有效控制肿瘤的生长，抑制肿瘤增殖，同时具有较高的安全性，对延长患者的生存时间、提高生存率具有重要的作用，值得临床应用推广。 |
| 关键词: 厄洛替尼 全脑放疗 非小细胞肺癌脑转移 临床疗效 预后 |
| DOI：10.3969/j.issn.1674-3806.2018.02.23 |
| 分类号:R 734.2 |
| 基金项目: |
|
| Erlotinib combined with whole brain radiotherapy for non-small cell lung cancer with brain metastasis and its prognosis |
|
LU Ai-li
|
|
Department of Radiation Oncology, the People′s Hospital of Zhenping County, Nanyang City, Henan 474250, China
|
| Abstract: |
| ［Abstract］ Objective To analyze the efficacy of erlotinib plus whole brain radiotherapy for non-small cell lung cancer with brain metastasis and its prognosis.Methods 90 patients with non-small cell lung cancer with brain metastases in our hospital were selected from May 2013 to July 2015 and were randomly divided into two groups, with 45 cases in each group. The control group was treated with whole brain radiotherapy for 3 weeks, with a total dose of 30 Gy/10 Fx. The observation group was treated with the same treatment as the control group plus erlotinib 150 mg/d for 3 weeks. The clinical efficacy, prognosis and the incidence of adverse reactions were compared between the two groups.Results In the observation group, complete renission(CR) was in 3 cases, partial(PR) in 25 cases, stable disease(SD) in 13 cases and progressive disease(PD) in 4 cases. In the control group, CR was in 1 case, PR in 16 cases, SD in 11 cases and PD in 17 cases. The clinical efficacy of the observation group was higher than that of the control group(P<0.01). The average survival time and survival rate of the observation group were significantly higher than those of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Erlotinib combined with whole brain radiotherapy can effectively control the tumor growth, inhibit the tumor proliferation, and prolong the survival time for the patients with non-small cell lung cancer and brain metastases. |
| Key words: Erlotinib Whole brain radiotherapy Brain metastasis of non-small cell lung cancer Clinical efficacy Prognosis |
